Pfizer to Acquire Seagen for ~$43B
- Pfizer will acquire Seagen for $229/per share in cash representing a total enterprise value of $43B while Seagen expects ~$2.2B of revenue in 2023 from its four in-line therapies & bringing Pfizer $10B+ in risk-adjusted revenues by 2030. The transaction is expected to be completed in late 2023 or early 2024
- The acquisition will combine Seagen’s ADC technology with Pfizer’s capabilities & expertise to bring new solutions to patients & also advance Seagen’s ADC technology to unlock novel target combinations & next-generation biologics
- Seagen’s portfolio incl. 4 approved medicines across solid tumors & hematologic malignancies, incl. 3 ADCs: Adcetris, Padcev & Tivdak. It also has a pipeline of drugs under development that incl. treatments for lung cancer & advanced breast cancer
Ref: Pfizer | Image: Pfizer
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.